Replies to post #24 on MediciNova, Inc. (MNOV)

[Tuff-Stuff]

MNOV 3.58 4:19AM MediciNova's MN-166 reduces persistent black hole formation in MS patients (MNOV) 3.58 :
52wk Range:3.30 - 13.99

Co announces additional data from a double-blind analysis of the first year of treatment from its two-year Phase II clinical trial of MN-166 in multiple sclerosis. The second year of the Phase II clinical trial is on-going with results expected in April 2008. The analysis showed that MN-166 decreased the formation of black holes (permanent brain lesions believed to indicate the death of nerves in the brain) on magnetic resonance imaging in MS patients, adding support to MediciNova's belief that MN-166 may provide neuroprotection in relapsing MS. Data demonstrated that a 60 mg/day dosing regimen of MN-166 significantly reduced the proportion of new T1 gadolinium-enhancing or new T2 lesions identified at month two of the study that evolved into persistent black holes at month 10 compared to placebo. Treatment with a 30 mg/day dosing regimen of MN-166 showed a trend toward reduced risk of new lesion evolution to persistent black holes compared to placebo.